Prestwick Pharmaceuticals Inc.
Division of Bausch Health Companies Inc./Biovail Corp.
Latest From Prestwick Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.'s bad luck in getting its experimental Huntington's disease drug deutetrabenazine (SD-809) across the FDA's finish line may be Neurocrine Bioscience's good fortune for its investigational agent valbenazine in another indication – tardive dyskinesia, a condition for which both companies are expected to file applications for their respective products in the US.
Unmet need is high in Huntington’s disease and the protracted review of Xenazine – the only drug cleared for the disease by FDA – suggests regulatory precedent for approval based on just one efficacy endpoint and with lots of development and safety baggage.
Less than three months after taking over as chairman and CEO of Yaupon Therapeutics, Steve Tullman has tapped up former Ception Therapeutics colleagues to make key appointments to his management team. Dr Tim Henkel, formerly VP of R&D at Ception will be VP of R&D; Doug Gessl, previously CFO at Ception, is appointed COO and CFO; Dr Jeffrey Wilkins, formerly Ception's VP of clinical development is appointed CMO. Rounding out the new management team: Dr Evan Dick, previously Ception's VP of discovery medicine & operations will be SVP of business development; Kelly Copeland, formerly Ception's VP of business development and product strategy is appointed VP of product strategy; Dr Jeffrey Shaver, who was Ception's VP of project management, alliances and information, will be VP of project management and operations; also a former Ception employee, Dr Jim Dowell has been appointed VP of biopharmaceutics. Other key hires include: Dr Martin Stogniew, formerly VP and CTO of Prestwick Pharmaceuticals, as VP of pharmaceutical sciences; and Dr Lisa Wittmer, previously VP and GM of Shire Pharmaceuticals' Emerging Products business unit, as VP of regulatory affairs. Ception Therapeutics was acquired by Cephalon in 2010.
Topaz Pharmaceuticals has appointed Bob Radie president and chief executive officer. Dr Thomas Beck, who has been serving as interim CEO, will resume his role as chief medical officer. Mr Radie was most recently President and CEO of TransMolecular, a biotech company developing cancer diagnostic and treatment products. He has also previously served as Chief Business Officer at Prestwick Pharmaceuticals (which was acquired by Biovail in 2008) and Morphotek (acquired by Eisai in 2007). Topaz’s lead product is ivermectin topical cream, which is concluding Phase III trials to support an NDA for the treatment of head lice.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Bausch Health Companies Inc.
- Valeant Pharmaceuticals International
- Senior Management
Bill W Bell , VP, Sales & Mktg.
Robert S Radie, EVP, CBO
David Stamler, MD, CSO
- Contact Info
Prestwick Pharmaceuticals Inc.
Phone: (202) 296-1400
1825 K St. NW, Ste. 1475
Washington, DC 20006
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.